- St. John's Hospital
- Cancer Institute
Adult Clinical Trials: LUNG
RTOG 0515: LUNG
A Comparative Study of Gross Tumor Volume Definition With or Without PET Fusion for Patients With Non-Small Cell Lung Carcinoma
- Pathologically (histologically or cytologically) proven diagnosis of non-small cell lung cancer
- Stage IIA/IIB or stage IIIA/B disease; patients with local or regional nodal recurrence following surgery are eligible
- Zubrod Performance Status 0, 1, or 2 and age >=18
- Pregnant women are not eligible
- Women of childbearing potential and male participants must practice adequate contraception
- Patient must sign study-specific informed consent prior to study entry
- Patients with malignant pleural effusion are not eligible
RTOG 0229: LUNG
A Phase II Trial of Neoadjuvant Therapy with Concurrent Chemotherapy and High Dose Radiotherapy Followed by Surgical Resection and Consolidative Therapy for Locally Advanced Non-Small Cell Lung Cancer
- Stage IIIA(T1-3 N2) or Stage IIIB (N3 excluding supraclavicular involvement ) by biopsy or cytology. Pancoast tumors are eligible if pathologic evidence of mediastinal nodal disease is present.
Treatment:
Induction Chemoradiation: Paclitaxel and Carboplatin 1x/week for 6 weeks plus Concurrent RT 1.8Gy/day, 5x/week, for a total of 50.4Gy in 28 fractions plus RT boost: 1.8Gy/day, 5x/week, for a total of l0.8Gy in 6 fractions. Reassessment: 4 weeks post Induction Chemoradiation: Resection: Consolidation Chemotherapy: Paclitaxel and Carboplatin q 21 days x 2.
